Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein - PubMed (original) (raw)
Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein
R C Kennedy et al. Science. 1986.
Abstract
In a study performed to determine which regions of the human T-cell lymphotrophic virus type III (HTLV-III) may represent vaccine candidates to prevent the acquired immune deficiency syndrome (AIDS), a synthetic peptide corresponding to amino acid sequence 735 to 752 of the precursor envelope glycoprotein of HTLV-III was used to immunize rabbits. The resulting rabbit antiserum to the synthetic peptide specifically recognized the precursor envelope glycoprotein (gp160) of HTLV-III. Human sera positive for antibody to HTLV-III reacted with this peptide. These findings indicate that synthetic peptides can be used to induce an immune response directed against a native envelope glycoprotein epitope of HTLV-III. The data are discussed in terms of using synthetic peptides to identify antigenic determinants involved in the induction of protective immunity and possibly as vaccine candidates against the etiologic agent of AIDS.
Similar articles
- Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.
Allan JS, Coligan JE, Barin F, McLane MF, Sodroski JG, Rosen CA, Haseltine WA, Lee TH, Essex M. Allan JS, et al. Science. 1985 May 31;228(4703):1091-4. doi: 10.1126/science.2986290. Science. 1985. PMID: 2986290 - Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.
Barin F, McLane MF, Allan JS, Lee TH, Groopman JE, Essex M. Barin F, et al. Science. 1985 May 31;228(4703):1094-6. doi: 10.1126/science.2986291. Science. 1985. PMID: 2986291 - Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).
Fischinger PJ, Robey WG, Koprowski H, Gallo RC, Bolognesi DP. Fischinger PJ, et al. Cancer Res. 1985 Sep;45(9 Suppl):4694s-4699s. Cancer Res. 1985. PMID: 2410115 Review. - Retroviruses associated with leukemia and ablative syndromes in animals and in human beings.
Essex M, McLane MF, Kanki P, Allan J, Kitchen L, Lee TH. Essex M, et al. Cancer Res. 1985 Sep;45(9 Suppl):4534s-4538s. Cancer Res. 1985. PMID: 2990682 Review.
Cited by
- Viral and Host Factors Regulating HIV-1 Envelope Protein Trafficking and Particle Incorporation.
Anokhin B, Spearman P. Anokhin B, et al. Viruses. 2022 Aug 5;14(8):1729. doi: 10.3390/v14081729. Viruses. 2022. PMID: 36016351 Free PMC article. Review. - Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion.
Narasimhulu VGS, Bellamy-McIntyre AK, Laumaea AE, Lay CS, Harrison DN, King HAD, Drummer HE, Poumbourios P. Narasimhulu VGS, et al. J Biol Chem. 2018 Apr 20;293(16):6099-6120. doi: 10.1074/jbc.RA117.000537. Epub 2018 Mar 1. J Biol Chem. 2018. PMID: 29496992 Free PMC article. - Solution Structure and Membrane Interaction of the Cytoplasmic Tail of HIV-1 gp41 Protein.
Murphy RE, Samal AB, Vlach J, Saad JS. Murphy RE, et al. Structure. 2017 Nov 7;25(11):1708-1718.e5. doi: 10.1016/j.str.2017.09.010. Epub 2017 Oct 19. Structure. 2017. PMID: 29056482 Free PMC article. - Differentiating founder and chronic HIV envelope sequences.
Murray JM, Maher S, Mota T, Suzuki K, Kelleher AD, Center RJ, Purcell D. Murray JM, et al. PLoS One. 2017 Feb 10;12(2):e0171572. doi: 10.1371/journal.pone.0171572. eCollection 2017. PLoS One. 2017. PMID: 28187204 Free PMC article. - Biophysical Characterization of a Vaccine Candidate against HIV-1: The Transmembrane and Membrane Proximal Domains of HIV-1 gp41 as a Maltose Binding Protein Fusion.
Gong Z, Martin-Garcia JM, Daskalova SM, Craciunescu FM, Song L, Dörner K, Hansen DT, Yang JH, LaBaer J, Hogue BG, Mor TS, Fromme P. Gong Z, et al. PLoS One. 2015 Aug 21;10(8):e0136507. doi: 10.1371/journal.pone.0136507. eCollection 2015. PLoS One. 2015. PMID: 26295457 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources